

REFERENCE 1

FAN.CNT 1

GI



AB Pipecolic acid derivs. are prepd. for treating vision disorders, improving vision, treating memory impairment, or enhancing memory performance in an animal. These compds. bind to immunophilin FKBP12 and preferably do not have immunosuppressive activity. Affinity for FKBP12 is measured as inhibition of prolyl peptidyl cis-trans isomerase (rotamase). Thus, pipecolic acid ester I inhibited rotamase with a K_i of 20 nM, showed a clearance rate of 41.8 $\mu\text{L}/\text{min}$, and rescued 56.6% of optic nerve axons from degeneration 14 days after optic nerve transection in rats (dose and route of administration not stated).

ST pipecolate deriv prepn vision memory disorder; immunophilin FKBP12 ligand vision memory disorder

IT Proteins, specific or class
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (FKBP (FK 506-binding protein); pipecolic acid derivs. for vision and memory disorders)

IT Proteins, specific or class
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (FKBP-12 (FK 506-binding protein, 12,000-mol.-wt.); pipecolic acid

derivs. for vision and memory disorders)
 IT Eye
 (conjunctiva, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Eye
 (cornea, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Immunity
 (disorder, of eye; pipecolic acid derivs. for vision and memory disorders)
 IT Lacrimal gland
 Memory, biological
 Vision
 (disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Memory, biological
 (enhancement of; pipecolic acid derivs. for vision and memory disorders)
 IT Radicals, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (eye disorders mediated by; pipecolic acid derivs. for vision and memory disorders)
 IT Vision
 (improvement of; pipecolic acid derivs. for vision and memory disorders)
 IT Eye, disease
 (injury; pipecolic acid derivs. for vision and memory disorders)
 IT Eye
 (lid, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Aging, animal
 (memory impairment in; pipecolic acid derivs. for vision and memory disorders)
 IT Structure-activity relationship
 (neuroprotectant; pipecolic acid derivs. for vision and memory disorders)
 IT Cytoprotective agents
 (neuroprotectants; pipecolic acid derivs. for vision and memory disorders)
 IT Brain
 (optic tract, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Nerve
 (optic, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT Cataract
 Eye, disease
 Oligodendrocyte
 (pipecolic acid derivs. for vision and memory disorders)
 IT Immunophilins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (pipecolic acid derivs. for vision and memory disorders)
 IT Eye, disease
 (retinopathy; pipecolic acid derivs. for vision and memory disorders)
 IT Eye
 (uvea, disorder; pipecolic acid derivs. for vision and memory disorders)
 IT 95076-93-0, Rotamase
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inhibition of; pipecolic acid derivs. for vision and memory disorders)
 IT 186268-50-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pipecolic acid derivs. for vision and memory disorders)
 IT 535-75-1D, Pipecolic acid, derivs. 53123-88-9, Rapamycin 141084-63-1

145021-36-9	145021-37-0	145021-38-1	145021-39-2	145021-41-6
145021-43-8	145021-46-1	145021-47-2	145021-65-4	145021-66-5
145021-67-6	145021-68-7	145037-51-0	147438-30-0	147438-31-1
148493-28-1	149438-31-3	152754-34-2	152754-35-3	152754-36-4
152754-37-5	152754-38-6	152754-39-7	152754-40-0	152754-41-1
152754-42-2	152754-55-7	153011-31-5,	SBL 506	155255-24-6
155255-27-9	155255-28-0	155255-29-1	155255-30-4	155255-31-5
155668-46-5	155668-47-6	155668-49-8	155668-50-1	155668-51-2
155668-52-3	155668-53-4	155668-54-5	155668-55-6	155668-56-7
155668-57-8	155668-58-9	155668-59-0	155668-60-3	155668-86-3
156038-45-8	157634-33-8	157634-34-9	157634-35-0	157757-22-7
157757-23-8	165047-17-6	186452-09-5,	GPI 1046	186834-62-8
186834-63-9	186834-64-0	186834-65-1	186834-66-2	186834-69-5
186834-70-8	186834-71-9	186834-72-0	186834-73-1	186834-74-2
186834-75-3	186834-76-4	186834-77-5	186834-78-6	186834-79-7
186834-80-0	186834-81-1	186834-82-2	186834-83-3	186834-84-4
186834-85-5	186834-86-6	186834-87-7	186834-88-8	186959-50-2
186959-54-6	186959-57-9	186959-60-4	186959-61-5	186959-77-3
186960-09-8	205388-16-5	205388-30-3	210048-30-9	210103-88-1
210103-92-7	212607-81-3	251950-42-2	251969-48-9	252002-58-7
252002-96-3	252770-38-0	252770-39-1	258871-54-4	259225-63-3
259225-64-4	259225-65-5	259225-66-6	259225-67-7	259225-68-8
259225-69-9	259225-70-2	259225-71-3	259225-72-4	259225-73-5
259225-74-6	259225-75-7	259225-76-8	259225-77-9	259225-78-0
259225-79-1				

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(pipecolic acid derivs. for vision and memory disorders)
IT 122-97-4, 3-Phenyl-1-propanol 2133-40-6, L-Proline methyl ester
hydrochloride 5781-53-3, Methyl oxalyl chloride 28276-08-6,
1,1-Dimethylpropylmagnesium chloride
RL: RCT (Reactant)

(pipecolic acid derivs. for vision and memory disorders)
IT 139419-63-9P 186268-77-9P 186268-78-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(pipecolic acid derivs. for vision and memory disorders)

REFERENCE 2

AN 132:26633 CA
TI Pipecolic acid derivatives for hair growth compositions
IN Hamilton, Gregory S.; Steiner, Joseph P.
PA Guilford Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K031-50; A61K031-435; A61K031-445; C07K005-02; C07K005-08
CC 62-3 (Essential Oils and Cosmetics)
Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9962483	A1	19991209	WO 1998-US11242	19980603
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9877167	A1	19991220	AU 1998-77167	19980603

PRAI WO 1998-US11242 19980603

AB This invention relates to pharmaceutical compns. and methods for treating

alopecia and promoting hair growth using pipecolic acid derivs. Thus, a hair lotion contained 95% EtOH, a pipecolic acid deriv. such as 4-(4-methoxyphenyl)butyl 1-(2-oxo-2-phenylacetyl)-2-piperidinecarboxylate 10.0, .alpha.-tocopherol acetate 0.01, ethoxylated hardened castor oil 0.5, and water 9.0%, and perfume and dye.

ST pipecolic acid deriv hair growth

IT Hair preparations

(creams; pipecolic acid derivs. for hair growth compns.)

IT Hair preparations

(emulsions; pipecolic acid derivs. for hair growth compns.)

IT Hair preparations

(growth stimulants; pipecolic acid derivs. for hair growth compns.)

IT Hair preparations

(lotions; pipecolic acid derivs. for hair growth compns.)

IT Alopecia

Immunosuppressants

Shampoos

(pipecolic acid derivs. for hair growth compns.)

IT Immunophilins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(pipecolic acid derivs. for hair growth compns.)

IT 535-75-1D, Pipecolic acid, derivs. 53123-88-9, Rapamycin 141084-63-1

145021-24-5 145021-25-6 145021-36-9 145021-37-0 145021-38-1

145021-39-2 145021-43-8 145021-46-1 145021-47-2 145037-51-0

147438-29-7 149438-31-3, Way 124466 152754-34-2 152754-35-3

152754-36-4 152754-37-5 152754-38-6 152754-39-7 152754-40-0

152754-41-1 152754-42-2 153011-31-5, SBL 506 155255-30-4

155255-31-5 155255-32-6 155367-80-9 155399-01-2 155399-02-3

155668-46-5 155668-47-6 155668-49-8 155668-50-1 155668-51-2

155668-52-3 155668-53-4 155668-54-5 155668-55-6 155668-56-7

155668-57-8 155668-58-9 155668-59-0 155668-61-4 155668-63-6

156038-45-8 157757-22-7 157757-23-8 186834-62-8 186834-63-9

186834-64-0 186834-65-1 186834-69-5 186834-70-8 186834-71-9

186959-50-2 186959-54-6 186959-57-9 186959-60-4 186959-61-5

186959-64-8 186959-67-1 186959-70-6 186959-77-3 186974-30-1

194232-17-2 194232-18-3 194232-19-4 251969-48-9 252002-37-2

252002-55-4 252002-58-7 252002-62-3 252002-64-5 252002-66-7

252002-68-9 252002-70-3 252002-75-8 252002-76-9 252002-79-2

252002-81-6 252002-83-8 252002-85-0 252002-87-2 252002-89-4

252002-91-8 252002-96-3 252002-98-5 252002-99-6 252003-00-2

252003-01-3 252003-02-4

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(pipecolic acid derivs. for hair growth compns.)

RE.CNT 6

(1) Armistead, D; US 5620971 A 1997 CAPLUS

(2) Astra Aktiebolaget; WO 9611943 A 1996 CAPLUS

(3) Fujisawa Pharm Co Ltd; EP 0423714 A 1987 CAPLUS

(4) Guilford Pharm; WO 9813343 A 1998 CAPLUS

(5) Nelson, F; US 5385908 A 1995 CAPLUS

(6) Skotnicki, J; US 5252579 A 1993 CAPLUS

REFERENCE 3

AN 128:70783 CA

TI Pipecolic acid derivative inhibitors of rotamase enzyme activity effective

at stimulating neuronal growth

IN Steiner, Joseph P.; Snyder, Solomon; Hamilton, Gregory S.

PA GPI NIL Holdings, Inc., USA; Johns Hopkins Univ. School of Medicines

SO U.S., 47 pp. Cont.-in-part of U.S. Ser. No. 474,072.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-445

ICS A61K038-18

NCL 514317000
 CC 1-11 (Pharmacology)
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5696135	A	19971209	US 1996-653905	19960528
	US 5798355	A	19980825	US 1995-474072	19950607
	CA 2206824	AA	19961219	CA 1996-2206824	19960605
	WO 9640140	A1	19961219	WO 1996-US9561	19960605
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9661622	A1	19961230	AU 1996-61622	19960605
	AU 710423	B2	19990923		
	DE 19680255	T	19970605	DE 1996-19680255	19960605
	EP 777478	A1	19970611	EP 1996-919227	19960605
	R: BE, FR, GR, IE, IT, MC, NL				
	CN 1187127	A	19980708	CN 1996-194555	19960605
	CH 689541	A	19990615	CH 1996-2789	19960605
	BR 9608485	A	19990706	BR 1996-8485	19960605
	ES 2138518	A1	20000101	ES 1996-50031	19960605
	ES 2138518	B1	20010101		
	FI 9604137	A	19970115	FI 1996-4137	19961015
	SE 9604097	A	19961208	SE 1996-4097	19961108
	DK 9601256	A	19961220	DK 1996-1256	19961108
	US 5843960	A	19981201	US 1997-787162	19970123
	US 5846981	A	19981208	US 1997-787163	19970123
	NO 9704290	A	19971204	NO 1997-4290	19970917
	LT 4516	B	19990625	LT 1998-2	19980106
	LV 11986	B	19980920	LV 1997-244	19980202
	US 6022878	A	20000208	US 1998-113330	19980710
	AU 9948793	A1	19991125	AU 1999-48793	19990916
PRAI	US 1995-474072		19950607		
	US 1996-653902		19960528		
	US 1996-653905		19960528		
	AU 1996-61622		19960605		
	WO 1996-US9561		19960605		
	US 1997-787162		19970123		
AB	A method is disclosed for using neurotrophic pipecolic acid deriv. compds. having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity assocd. with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration. The compds. of the invention are useful for treatment of neurol. disorders.				
ST	neuron growth pipecolate deriv rotamase inhibitor; regeneration neuron pipecolate deriv rotamase inhibitor; neurol disorder pipecolate deriv rotamase inhibitor				
IT	mRNA RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (FKBP and GAP-43; pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)				
IT	Transport (biological) (FKBP; pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)				
IT	Stroke (brain damage-assocd.; pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and				

treating neurol. disorders)

IT Nerves
(facial; pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT Growth factors (animal)
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(neurite extension factors; pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT Alzheimer's disease
Amyotrophic lateral sclerosis
Brain injury
Nerve degeneration
Nervous system agents
Nervous system diseases
Neurons
PC12 cell
Parkinson's disease
Peripheral nerve injury
Peripheral neuropathy
Sciatic nerve
Spinal cord injury
Spinal ganglion
(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT FKBP (protein)
FKBP12 (protein)
GAP-43 (protein)
Immunophilins
Myelin
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT Brain-derived neurotrophic factor
Ciliary neurotrophic factor
Glial-derived neurotrophic factor
Neurotrophic factors
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders, and use with neurotrophic factors)

IT 9061-61-4, Nerve growth factor 53123-88-9, Rapamycin 59865-13-3, Cyclosporin A 149438-31-3, WAY-124466
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT 104987-11-3
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT 535-75-1D, Pipecolic acid, derivs. 141084-63-1 152754-33-1
152754-34-2 152754-35-3 152754-36-4 152754-42-2 155668-86-3
157757-22-7 186834-66-2 186834-69-5 186834-70-8 186834-71-9
186834-72-0 186834-73-1 186834-74-2 186834-75-3 186834-76-4
186834-77-5 186834-78-6 186834-79-7 186834-80-0 186834-81-1
186834-82-2 186834-83-3 186834-84-4 186834-85-5 186834-86-6

186834-87-7 186834-88-8 200417-73-8 200728-03-6 200728-04-7

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT 9025-75-6, Calcineurin 95076-93-0, Rotamase

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol. disorders)

IT 130939-66-1, Neurotrophin 3

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(pipecolic acid deriv. inhibitors of rotamase enzyme activity for stimulating neuronal growth and regeneration and treating neurol.

L27 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 53123-88-9 REGISTRY

CN Rapamycin (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, rapamycin deriv.

OTHER NAMES:

CN (-)-Rapamycin

CN (3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 19E, 21S, 23S, 26R, 27R, 34aS) - 9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 34a-Hexadecahydro-9, 27-dihydroxy-3-[(1R)-2-[(1S, 3R, 4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10, 21-dimethoxy-6, 8, 12, 14, 20, 26-hexamethyl-23, 27-epoxy-3H-pyrido[2, 1-c][1, 4]oxaazacyclohentriacontine-1, 5, 11, 28, 29(4H, 6H, 31H)-pentone

CN 23, 27-Epoxy-3H-pyrido[2, 1-c][1, 4]oxaazacyclohentriacontine-1, 5, 11, 28, 29(4H, 6H, 31H)-pentone, 9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33,

34, 34a-hexadecahydro-9, 27-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl]-10, 21-dimethoxy-6, 8, 12, 14, 20, 26-hexamethyl-,

[3S-[3R*[S*(1R*, 3S*, 4S*)], 6S*, 7E, 9S*, 10S*, 12S*, 14R*, 15E, 17E, 19E, 21R*, 23R*, 26S*, 27S*, 34aR*]]-

CN Antibiotic AY 22989

CN AY 22989

CN Rapamune

CN SIIA 9268A

CN Sirolimus

CN

[3S-[3R*[S*(1R*, 3S*, 4S*)], 6S*, 7E, 9S*, 10S*, 12S*, 14R*, 15E, 17E, 19E, 21R*, 23R*, 26S*, 27S*, 34aR*]]-9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 34a-Hexadecahydro-9, 27-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl]-10, 21-dimethoxy-6, 8, 12, 14, 20, 26-hexamethyl-23, 27-epoxy-3H-pyrido[2, 1-c][1, 4]oxaazacyclohentriacontine-1, 5, 11, 28, 29(4H, 6H, 31H)-pentone

FS STEREOSEARCH

MF C51 H79 N O13

CI COM

LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,

MRCK*,


MSDS-OHS, NAPRALERT, PHAR, PROMT, RTECS*, SYNTHLINE, TOXLINE, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Double bond geometry as shown.



Me

1328 REFERENCES IN FILE CA (1967 TO DATE)
 77 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1334 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS

AB . . . isomerase or rotamase enzyme activity, to stimulate or promote neuronal growth or regeneration. The compds, of the invention (e.g. Way-124,666; **SLB-506**) are useful for the treatment of neurol. disorders. The compds. may be used in conjunction with a neurotrophic factor (neurotrophic. . .

ACCESSION NUMBER: 1997:151523 CAPLUS

DOCUMENT NUMBER: 126:152817

TITLE: Pipecolic acid derivatives as inhibitors of rotamase activity, and use in treatment of nervous system disorders.

INVENTOR(S): Steiner, Joseph P.; Snyder, Solomon; Hamilton, Gregory

PATENT ASSIGNEE(S): S.
Guilford Pharmaceuticals Inc., USA; Johns Hopkins University School of Medicine

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640140	A1	19961219	WO 1996-US9561	19960605
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN			
US 5798355	A	19980825	US 1995-474072	19950607
US 5696135	A	19971209	US 1996-653905	19960528
AU 9661622	A1	19961230	AU 1996-61622	19960605
AU 710423	B2	19990923		
DE 19680255	T	19970605	DE 1996-19680255	19960605
EP 777478	A1	19970611	EP 1996-919227	19960605
R:	BE, FR, GR, IE, IT, MC, NL			
BR 9608485	A	19990706	BR 1996-8485	19960605
FI 9604137	A	19970115	FI 1996-4137	19961015
SE 9604097	A	19961208	SE 1996-4097	19961108
DK 9601256	A	19961220	DK 1996-1256	19961108
NO 9704290	A	19971204	NO 1997-4290	19970917
AU 9948793	A1	19991125	AU 1999-48793	19990916
PRIORITY APPLN. INFO.:			US 1995-474072	19950607
			US 1996-653905	19960528
			US 1996-653902	19960528
			AU 1996-61622	19960605
			WO 1996-US9561	19960605

=> s 119 and (vision or memory)

5930 VISION

63635 MEMORY

L21 0 L19 AND (VISION OR MEMORY)

(copy file #1)

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 149438-31-3 REGISTRY

CN 27,31-Epoxy-5,36-etheno-1H,5H-pyrido[2,1-c][1,2,4]triazolo[1,2-

q][1,4,17,18]oxatriazacyclohentriacontine-1,3,9,15,19,25,26(2H,6H,10H,19aH)
)-heptone, 7,8,11,14,16,17,20,21,22,23,27,28,29,30,31,32,33,36-
octadecahydro-11,27-dihydroxy-17-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-
methoxycyclohexyl]-1-methylethyl]-10,33-dimethoxy-6,8,12,14,28,34-
hexamethyl-2-phenyl-,
(6S,8R,10R,11R,12E,14R,17S,19aS,27R,28R,31S,33S,34E)-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 27,31-Epoxy-5,36-etheno-1H,5H-pyrido[2,1-c][1,2,4]triazolo[1,2-

q][1,4,17,18]oxatriazacyclohentriacontine-1,3,9,15,19,25,26(2H,6H,10H,19aH)
)-heptone, 7,8,11,14,16,17,20,21,22,23,27,28,29,30,31,32,33,36-
octadecahydro-11,27-dihydroxy-17-[2-(4-hydroxy-3-methoxycyclohexyl)-1-
methylethyl]-10,33-dimethoxy-6,8,12,14,28,34-hexamethyl-2-phenyl-,

[6S-[6R*,8S*,10S*,11S*,12E,14S*,17R*[S*(1R*,3S*,4S*)],19aR*,27S*,28S*,31R*
,33R*,34E]]-[partial]-

OTHER NAMES:

CN WAY 124466

FS STEREOSEARCH

MF C59 H84 N4 O15

SR CA

LC STN Files: CA, CANCERLIT, CAPLUS, MEDLINE, TOXLINE, TOXLIT, USPATFULL

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
=====	=====	=====	=====	=====	=====
C6	C6	6	C6	46.150.1	1
C6	C6	6	C6	46.150.18	1
C2N3-C4N2-	N2CNC-N2C4-	5-6-6-6-29	C35N4O2	55790.1.1	1
C5N-C5O-	NC5-OC5-				
C24N3O2	N2C6OC3NC2OC1				
	3				

Absolute stereochemistry.

Double bond geometry as described by E or Z.

Currently available stereo shown.

